Adenovirus with hexon tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors

Journal of Virology

Volumn 85, Issue 24, 2011, Pages 13114-13123

  Yu, Di ^a   Jin, Chuan ^a   Leja, Justyna ^a   Majdalani, Nadim ^b   Nilsson, Berith ^a   Eriksson, Fredrik ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; ONCOLYTIC ADENOVIRUS; TRANSACTIVATOR PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; COXSACKIE VIRUS; DNA MODIFICATION; DRUG CYTOTOXICITY; FEMALE; GENE CONSTRUCT; GENE VECTOR; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MOUSE; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRUSES, HUMAN; ANIMALS; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; NEUROBLASTOMA; NEUROENDOCRINE TUMORS; ONCOLYTIC VIRUSES; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSDUCTION, GENETIC; TREATMENT OUTCOME; VIRUS INTERNALIZATION;

ADENOVIRIDAE; COXSACKIEVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84855857744     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05759-11     Document Type: Article

References (52)

1. Alba, R., et al. 2009. Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114:965-971.
2. Bauerschmitz, G. J., et al. 2004. Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer. Int. J. Cancer 111:303-309.
3. Bjorke, H., and K. Andersson. 2006. Automated, high-resolution cellular retention and uptake studies in vitro. Appl. Radiat. Isot. 64:901-905.
4. Boulanger, P. A., and F. Puvion. 1973. Large-scale preparation of soluble adenovirus hexon, penton and fiber antigens in highly purified form. Eur. J. Biochem. 39:37-42.
5. Bridle, B. W., et al. 2010. Potentiating cancer immunotherapy using an oncolytic virus. Mol. Ther. 18:1430-1439.
6. Carlsson, B., W. S. Cheng, T. H. Totterman, and M. Essand. 2003. Ex vivo stimulation of cytomegalovirus (CMV)-specific T cells using CMV pp65-modified dendritic cells as stimulators. Br. J. Haematol. 121:428-438.
7. Cheng, W. S., et al. 2004. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol. Ther. 10:355-364.
8. Corjon, S., et al. 2008. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol. Ther. 16:1813-1824.
9. Danielsson, A., H. Dzojic, B. Nilsson, and M. Essand. 2008. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPTE1A] by reduction of the insulator size and introduction of the full-length E3 region. Cancer Gene Ther. 15:203-213.
10. Danielsson, A., et al. 2010. An ex vivo loop system models the toxicity and efficacy of PEGylated and unmodified adenovirus serotype 5 in whole human blood. Gene Ther. 17:752-762.
11. Eiriksdottir, E., K. Konate, U. Langel, G. Divita, and S. Deshayes. 2010. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim. Biophys. Acta 1798:1119-1128.
12. El-Andaloussi, S., T. Holm, and U. Langel. 2005. Cell-penetrating peptides: mechanisms and applications. Curr. Pharm. Des. 11:3597-3611.
13. Ellis, L. M., S. Samuel, and E. Sceusi. Varying opinions on the authenticity of a human midgut carcinoid cell line. Clin. Cancer Res. 16:5365-5366. (Letter.)
14. Essand, M., J. Leja, V. Giandomenico, and K. E. Oberg. 2011. Oncolytic viruses for the treatment of neuroendocrine tumors. Horm. Metab. Res. doi:10.1055/s-0031-1277225.
15. Eto, Y., et al. 2009. Transduction of adenovirus vectors modified with cellpenetrating peptides. Peptides 30:1548-1552.
16. Fallaux, F. J., et al. 1996. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum. Gene Ther. 7:215-222.
17. Franqueville, L., et al. 2008. Protein crystals in Adenovirus type 5-infected cells: requirements for intranuclear crystallogenesis, structural and functional analysis. PLoS One 3:e2894.
18. Froidevaux, S., and F. Loor. 1991. A quick procedure for identifying doubly homozygous immunodeficient scid beige mice. J. Immunol. Methods 137: 275-279.
19. Fueyo, J., et al. 2000. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2-12.
20. Fukazawa, T., et al. 2010. Adenovirus-mediated cancer gene therapy and virotherapy. Int. J. Mol. Med. 25:3-10.
21. Geoerger, B., et al. 2005. Expression of p53, or targeting toward EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J. Gene Med. 7:584-594.
22. Kreppel, F., J. Gackowski, E. Schmidt, and S. Kochanek. 2005. Combined genetic and chemical capsid modifications enable flexible and efficient deand retargeting of adenovirus vectors. Mol. Ther. 12:107-117.
23. Kurachi, S., et al. 2007. Fiber-modified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity. Gene Ther. 14:1160-1165.
24. Lambert, C., N. Leonard, X. De Bolle, and E. Depiereux. 2002. ESyPred3D: prediction of proteins 3D structures. Bioinformatics 18:1250-1256.
25. Leifert, J. A., S. Harkins, and J. L. Whitton. 2002. Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. Gene Ther. 9:1422-1428.
26. Leja, J., et al. 2007. A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin. Cancer Res. 13:2455-2462.
27. Leja, J., et al. 2010. Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS One 5:e8916.
28. Leja, J., et al. 2011. Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells. Gene Ther. doi: 10.1038/gt.2011.54.
29. Parikh, N. S., et al. 2005. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr. Blood Cancer 44:469-478.
30. Pesonen, S., et al. 2010. Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther. 17:892-904.
31. Rebetz, J., et al. 2009. Fiber mediated receptor masking in non-infected bystander cells restricts adenovirus cell killing effect but promotes adenovirus host co-existence. PLoS One 4:e8484.
32. Roberts, D. M., et al. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting anti-vector immunity. Nature 441:239-243.
33. Rux, J. J., P. R. Kuser, and R. M. Burnett. 2003. Structural and phylogenetic analysis of adenovirus hexons by use of high-resolution x-ray crystallographic, molecular modeling, and sequence-based methods. J. Virol. 77: 9553-9566.
34. Sawant, R., and V. Torchilin. 2010. Intracellular transduction using cellpenetrating peptides. Mol. Biosyst. 6:628-640.
35. Schaeffer, C., and M. A. Warso. 2009. A phase I trial of p28 (cell penetrating peptide) in the treatment of refractory solid tumors. http://clinicaltrials.gov/ct2/show/NCT00914914.
36. Seregin, S. S., and A. Amalfitano. 2009. Overcoming preexisting adenovirus immunity by genetic engineering of adenovirus-based vectors. Expert Opin. Biol. Ther. 9:1521-1531.
37. Shashkova, E. V., S. M. May, K. Doronin, and M. A. Barry. 2009. Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol. Ther. 17:2121-2130.
38. Stanton, R. J., B. P. McSharry, M. Armstrong, P. Tomasec, and G. W. Wilkinson. 2008. Re-engineering adenovirus vector systems to enable highthroughput analyses of gene function. Biotechniques 45:659-. 62:664-668.
39. Terao, S., et al. 2009. Improved gene transfer into renal carcinoma cells using adenovirus vector containing RGD motif. Anticancer Res. 29:2997-3001.
40. Thomas, M. A., D. L. Lichtenstein, P. Krajcsi, and W. S. Wold. 2007. A real-time PCR method to rapidly titer adenovirus stocks. Methods Mol. Med. 130:185-192.
41. Thorne, S. H., et al. 2010. Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. Mol. Ther. 18:1698-1705.
42. Tollefson, A. E., M. Kuppuswamy, E. V. Shashkova, K. Doronin, and W. S. Wold. 2007. Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol. Med. 130:223-235.
43. Van Buren, G., 2nd, et al. 2007. The development and characterization of a human midgut carcinoid cell line. Clin. Cancer Res. 13:4704-4712.
44. Vellinga, J., et al. 2007. Efficient incorporation of a functional hyper-stable single-chain antibody fragment protein-IX fusion in the adenovirus capsid. Gene Ther. 14:664-670.
45. Vigant, F., et al. 2008. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. 16:1474-1480.
46. Vigne, E., et al. 1999. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 73:5156-5161.
47. Waddington, S. N., et al. 2008. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132:397-409.
48. Wang, H., et al. 2011. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11, and 14. Nat. Med. 17:96-104.
49. Wang, H., et al. 2007. Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J. Virol. 81:12785-12792.
50. Wu, H., et al. 2005. Identification of sites in adenovirus hexon for foreign peptide incorporation. J. Virol. 79:3382-3390.
51. Yoshioka, Y., et al. 2008. Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sci. 83:747-755.
52. Zhang, Y. Q., Y. C. Tsai, A. Monie, T. C. Wu, and C. F. Hung. 2010. Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol. Ther. 18:692-699.